307 related articles for article (PubMed ID: 35739428)
61. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
Dumas PY; Villacreces A; Guitart AV; El-Habhab A; Massara L; Mansier O; Bidet A; Martineau D; Fernandez S; Leguay T; Pigneux A; Vigon I; Pasquet JM; Desplat V
Clin Cancer Res; 2021 Nov; 27(21):6012-6025. PubMed ID: 34400415
[TBL] [Abstract][Full Text] [Related]
62. Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat
Molica M; Perrone S; Rossi M
J Clin Med; 2023 May; 12(11):. PubMed ID: 37297842
[TBL] [Abstract][Full Text] [Related]
63. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J; Song Y; Liu D
Biomark Res; 2019; 7():19. PubMed ID: 31528345
[TBL] [Abstract][Full Text] [Related]
64. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver TC; Hill JE; Rahmat L; Perl AE; Bahceci E; Mori K; Smith CC
Blood Adv; 2020 Feb; 4(3):514-524. PubMed ID: 32040554
[TBL] [Abstract][Full Text] [Related]
65. Gilteritinib induces differentiation in relapsed and refractory
McMahon CM; Canaani J; Rea B; Sargent RL; Qualtieri JN; Watt CD; Morrissette JJD; Carroll M; Perl AE
Blood Adv; 2019 May; 3(10):1581-1585. PubMed ID: 31122910
[TBL] [Abstract][Full Text] [Related]
66. Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.
Oncologist; 2021 Feb; 26 Suppl 1(Suppl 1):S10. PubMed ID: 33368797
[TBL] [Abstract][Full Text] [Related]
67. Availability of FLT3 inhibitors: how do we use them?
Perl AE
Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
[TBL] [Abstract][Full Text] [Related]
68. Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293564
[TBL] [Abstract][Full Text] [Related]
69. Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.
Zeidan AM; Qi CZ; Yang H; Garnham A; Shah MV; Pandya BJ
Leuk Lymphoma; 2022 Mar; 63(3):762-764. PubMed ID: 34749571
[No Abstract] [Full Text] [Related]
70. 4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition.
Zhao XY; Zhang RR; Ye Q; Qiu F; Xu HY; Wei FG; Zhang H
Curr Med Sci; 2020 Oct; 40(5):810-816. PubMed ID: 33123895
[TBL] [Abstract][Full Text] [Related]
71. Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with
Ritchie EK; Cella D; Fabbiano F; Pigneux A; Kanda Y; Ivanescu C; Pandya BJ; Shah MV
Leuk Lymphoma; 2023 May; 64(5):938-950. PubMed ID: 37019445
[TBL] [Abstract][Full Text] [Related]
72. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
Kida M; Kuroda Y; Kido M; Chishaki R; Kuraoka K; Ito T
Int J Hematol; 2020 Aug; 112(2):243-248. PubMed ID: 32170661
[TBL] [Abstract][Full Text] [Related]
73. The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.
Qiao X; Ma J; Knight T; Su Y; Edwards H; Polin L; Li J; Kushner J; Dzinic SH; White K; Wang J; Lin H; Wang Y; Wang L; Wang G; Taub JW; Ge Y
Blood Cancer J; 2021 Jun; 11(6):111. PubMed ID: 34099621
[TBL] [Abstract][Full Text] [Related]
74. Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study.
Bazzell BG; Marini BL; Benitez LL; Bixby D; Burke P; Pettit K; Perissinotti AJ
J Oncol Pharm Pract; 2022 Sep; 28(6):1315-1325. PubMed ID: 34074182
[TBL] [Abstract][Full Text] [Related]
75. Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia.
Han H; Shin DY; Kim D; Kim H; Lee C; Koh Y; Hong J; Yoon SS
Leuk Lymphoma; 2020 Aug; 61(8):1932-1942. PubMed ID: 32374198
[TBL] [Abstract][Full Text] [Related]
76. The FLT3
Joshi SK; Pittsenbarger J; Kennedy VE; Peretz CAC; Perl AE; Smith CC; Tyner JW; Druker BJ; Traer E
Am J Hematol; 2023 Dec; 98(12):E364-E368. PubMed ID: 37815132
[No Abstract] [Full Text] [Related]
77. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
78. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Scholl S; Fleischmann M; Schnetzke U; Heidel FH
Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
[TBL] [Abstract][Full Text] [Related]
79. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
80. [FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].
Kawashima N
Rinsho Ketsueki; 2021; 62(8):954-966. PubMed ID: 34497236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
